Anti Inflammatory News and Research

RSS

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

Statins activate bacterial-killing properties of white blood cells

Widely prescribed for their cholesterol-lowering properties, recent clinical research indicates that statins can produce a second, significant health benefit: lowering the risk of severe bacterial infections such as pneumonia and sepsis.

18 Nov 2010

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

Idera Pharmaceuticals, Inc. announced today that it is presenting preclinical data from a study evaluating the mechanism of action of one of its Toll-like receptor (TLR) 7 and TLR9 antagonist candidates in a model of hyperlipidemia.

18 Nov 2010

FDA grants three years of marketing exclusivity to ISTA's BROMDAY

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act.

18 Nov 2010

Research on CBS protein may lead to new drug design for homocystinuria disorder

University of Michigan researchers have solved the structure of a protein that is integral to processes responsible for maintaining a healthy heart and nervous system.

17 Nov 2010

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Fisetin, a naturally occurring compound found in strawberries and other fruits and vegetables, slows the onset of motor problems and delays death in three models of Huntington's disease, according to researchers at the Salk Institute for Biological Studies. The study, published in the online edition of Human Molecular Genetics, sets the stage for further investigations into fisetin's neuroprotective properties in Huntington's and other neurodegenerative conditions.

16 Nov 2010

VIMOVO granted marketing and pricing approval in the UK

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has been notified by AstraZeneca that marketing and pricing approval for VIMOVO™ (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets, has been granted in the United Kingdom (UK).

12 Nov 2010

Dreaded cod liver oil in a variety of flavours

The stomachs of the generation of 50 year olds and above, will be churning at the thought of their parents and grandparents serving up spoonfuls of the much dreaded cod liver oil. As a practice, parents giving their children cod liver oil has all but died, and yet, as a population, we have seen more and more inflammatory conditions effect people's lives, which are due in no small part to the 'modern day diet', which many of us live.

12 Nov 2010

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.

12 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).

10 Nov 2010

L. reuteri Prodentis effective for treating chronic periodontitis

The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis.

10 Nov 2010

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia

9 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

NUVO announces positive results from WF10 Phase 2 clinical trial for severe allergic rhinitis

Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.

8 Nov 2010

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Santarus, Inc. a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate active ulcerative colitis.

8 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Anti Inflammatory News and Research

New findings show promising treatment for MS

Statins activate bacterial-killing properties of white blood cells

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

FDA grants three years of marketing exclusivity to ISTA's BROMDAY

Research on CBS protein may lead to new drug design for homocystinuria disorder

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

VIMOVO granted marketing and pricing approval in the UK

Dreaded cod liver oil in a variety of flavours

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

L. reuteri Prodentis effective for treating chronic periodontitis

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

DHA protects brain tissue and promotes recovery in acute ischemic stroke

NUVO announces positive results from WF10 Phase 2 clinical trial for severe allergic rhinitis

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Study suggests bacterial products contribute to autoimmune diseases

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News